THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

MAIA Biotechnology receives USAN Council approval for “ateganosine” as nonproprietary name for anticancer agent THIO: Chicago Friday, March 21, 2025, 14:00 Hrs [IST] MAIA Biot ...

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

“THIO has consistently and substantially outperformed standard treatment options in our THIO-101 Phase 2 trial to date. THIO-104 will give us direct comparative data from a randomized study in ...

Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were ...

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In ...

Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance MAIA Biotechnology, Inc., (NYSE American ...

MAIA Biotechnology (MAIA) announced that the United States Adopted Names Council has approved “ateganosine” as the nonproprietary name for its ...

“The designation of a new nonproprietary name for THIO is a key step along our development and regulatory pathway as we move forward with Phase 2 and 3 clinical trials,” said Vlad ...